Healthcare Industry News:  HIFU therapy 

Devices Oncology

 News Release - December 18, 2006

EDAP Announces Second Sale to Maple Leaf HIFU

Canadian Medical Company Secures Second Ablatherm in North America

LYON, France, Dec. 18 (HSMN NewsFeed) -- EDAP TMS S.A. (Nasdaq: EDAP ), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, announces the sale of its second Ablatherm HIFU medical device in Canada. Maple Leaf HIFU, the largest provider of HIFU therapy for localized prostate cancer in Canada, will take delivery of the unit by year end. Maple Leaf already operates a successful and growing HIFU practice based at the Don Mills Surgical Hospital in Toronto, Canada.

EDAP CEO Hugues de Bantel stated, "We are excited to place our second Ablatherm HIFU unit in Canada where Maple Leaf has built a successful and growing practice providing North American men with a demonstrated effective therapy for localized prostate cancer without forcing them to accept significant side effects or risk their quality of life. We continue to see a strong response from Canada and all centers worldwide as patients and physicians learn of the strong benefits available with the Ablatherm as a noninvasive therapy option offering strong outcomes. The success of Maple Leaf clearly demonstrates the attractiveness of Ablatherm HIFU to patients as well as the growing market demand for new therapies without the lifestyle compromises often risked by traditional treatment methods."

The second unit was purchased in response to growing demand for HIFU care at Maple Leaf's Toronto center serving patients from all of North America since the launch of services in April 2005. Approximately 50 percent of patients treated travel to Toronto from the United States. Additionally, doctors from across North America attend treatment sessions to learn about HIFU therapy and its unique benefits as a new therapeutic option for urologists to treat patients not eligible or not interested in surgical care.

Dr. William Orovan, Chair of the Department of Surgery, Faculty of Health Sciences, McMaster University commented, "Since commencing Ablatherm HIFU treatments in the Spring of 2005 in Toronto we have seen a significant increase in patient volume, particularly from our American neighbors. Our patients have been extremely satisfied. I am confident that Ablatherm HIFU's popularity is going to continue to grow as more people in North America become aware of its benefits."

Dr. Magdy Hassouna, who has treated more than 50 patients, stated, "We continue to see growing interest by men from North America in seeking treatment options that provide rapid care, high confidence of successful outcomes and low side effects. Quality of life is today more important than ever and patients are more often researching their care choices in search of quality options in place of traditional therapies where the outcomes may leave them at risk of incontinence, impotence or recurrence. Ablatherm-HIFU offers them a quality treatment with consistent success and low side effects allowing them to rapidly return to their lifestyle. We recently presented our data at an American Urological Association meeting, the first Ablatherm-HIFU data presented from the commercial use of HIFU in North America, demonstrating clear success measured by a reduction of PSA, typically observing the nadir in just three months. In this patient population we were able to report no significant side effects and strong success."

Dr. Hassouna is certified as a Fellow by the American College of Surgeons and by the College of Physicians and Surgeons of Canada. He is also a Diplomat of the American Board of Urology, an Associate Professor of Urology at the University of Toronto and a Senior Investigator at the Toronto Western Hospital Research Institute where his research has focused on treatment of lower urinary tract disorders including Prostate Cancer.

About Maple Leaf HIFU Co.

Maple Leaf HIFU Co. is a privately held Canadian medical services company offering treatments using AblathermŽ-High Intensity Focused Ultrasound treatments for localized prostate cancer. Further information can be found at .


EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically proven choice for High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. The company is also developing this technology for the potential treatment of certain other types of tumors. EDAP TMS S.A. also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL).

For more information on the Company, contact Halliburton Investor Relations at (972) 458-8000, the Corporate Investor Relations Dept at +33 (0)4 78 26 40 46 or see the Company's Web sites at and .

In addition to historical information, this press release contains forward-looking statements that involve risks and uncertainties. These include statements regarding the Company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in these forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission. Ablatherm- HIFU treatment is in clinical trials but not yet FDA approved or marketed in the United States.

Source: EDAP TMS

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.